AstraZeneca
NEWS
As a private company, Moderna has amassed a significant fortune of billions of dollars and a valuation of about $7 billion – all of this without any marketed product in the company’s field of messenger RNA (mRNA).
Indianapolis-based Eli Lilly pulled another BACE therapy from its pipeline, the company announced in a third-quarter conference call.
AstraZeneca has spent the last seven years getting hammered by loss of patent protections on older drugs. However, this quarter marked a return to sales growth driven by high demand for its new drugs, especially in the oncology segment.
AstraZeneca is unloading rights to Alvesco (ciclesonide) to treat persistent asthma, and Omnaris and Zetonna (ciclesonide) to treat nasal symptoms associated with rhinitis. The company indicates that the rights cover markets outside the United States and the U.S. royalties for the drugs.
According to the American Cancer Society, almost 601,000 people in the U.S. died of cancer in 2017. The two most common types of cancer are lung cancer and breast cancer, followed by colorectal cancer, prostate cancer and stomach cancer.
Privately-held Grunenthal GmbH will pay AstraZeneca $700 million for the prescription medicine rights to acid-reflux medicine Nexium. The deal with AstraZeneca represents the largest investment in Grünenthal company history.
Abdul Rahman bin Mohammed Al Owais, UAE Minister of Health and Prevention, signed a partnership agreement with Leif Johansson, Chairman of leading global pharmaceutical company AstraZeneca, as part of its strategy to enhance the outcomes of national indicators in the field of respiratory diseases and cancer, to achieve the objectives of the National Agenda 2021.
However, because the trial did show some efficacy and met other secondary endpoints, the companies are continuing to analyze the data and decide on their next moves.
French company Innate Pharma and UK-based AstraZeneca have had a research collaboration deal in place since 2015. The two companies announced a new multi-term deal to build on that collaboration.
JOBS
IN THE PRESS